NASDAQ:ALZN
Alzamend Neuro, Inc.
- Stock
Last Close
0.62
16/05 20:00
Market Cap
5.77M
Beta: -
Volume Today
94.11K
Avg: 184.60K
PE Ratio
−0.38
PFCF: −0.69
Apr '19 | Apr '20 | Apr '21 | Apr '22 | Apr '23 | ||
|---|---|---|---|---|---|---|
asset turnover | ||||||
cash per share | 0.00 - | 0.00 109.52% | 0.02 2,158.48% | 0.16 594.89% | 0.05 66.60% | |
company equity multiplier | 4.74 - | 2.21 53.39% | 1.45 34.46% | 1.09 24.86% | 1.94 78.65% | |
days of inventory outstanding | ||||||
days of payables outstanding | ||||||
days of sales outstanding | ||||||
dividend yield | ||||||
ebit per revenue | ||||||
ebt per ebit | 0.97 - | 1.00 2.69% | 1.02 2.23% | 1.00 1.54% | 1.00 0.29% | |
effective tax rate | 0.03 - | 0.00 89.51% | -0.03 1,085.91% | -0.00 88.95% | ||
enterprise value multiple | -239.20 - | -273.88 14.50% | -231.30 15.55% | -6.24 97.30% | -3.14 49.60% | |
fixed asset turnover | ||||||
free cash flow per share | -0.01 - | -0.03 121.91% | -0.03 22.19% | -0.08 136.22% | -0.09 21.31% | |
gross profit margin | ||||||
interest coverage | -31.18 - | -264.80 749.19% | -1.93K 629.22% | |||
inventory turnover | ||||||
long term debt to capitalization | ||||||
net income per ebt | 1 - | 1.00 0.32% | 1.03 3.44% | 1.00 2.69% | 1 0.34% | |
net profit margin | ||||||
operating cash flow per share | -0.01 - | -0.03 121.91% | -0.03 22.19% | -0.07 132.47% | -0.09 23.26% | |
operating profit margin | ||||||
payables turnover | ||||||
pretax profit margin | ||||||
price fair value | 3.78K - | 1.47K 60.99% | 569.59 61.38% | 6.81 98.81% | 17.01 149.95% | |
receivables turnover | ||||||
return on assets | -3.24 - | -2.42 25.19% | -1.79 26.28% | -0.85 52.17% | -2.52 194.32% | |
return on capital employed | -15.81 - | -5.38 65.93% | -2.46 54.31% | -0.92 62.49% | -4.88 429.18% | |
return on equity | -15.34 - | -5.35 65.13% | -2.59 51.68% | -0.93 64.06% | -4.89 425.82% | |
total debt to capitalization | 0.14 - |
All numbers in USD (except ratios and percentages)